Medical Affairs in recent times has stepped out of the background to become a core strategic partner in pharma and biotech companies. No longer just a support team, MA is at the forefront — blending science, business, and healthcare to create a development process that is faster and deeply centred on patient needs.
Medical affairs is an increasingly complex discipline. It is vital that the team is highly trained and able to adapt to an evolving environment, liaising effectively with stakeholders to communicate value and bring new treatments to the market. Read on to discover some of the challenges and trends affecting the sector.
A report commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has led the organisation to warn that the options being discussed by policymakers around the EU Pharma Strategy fall short.
